Scope and claim strategy for US Patent 8,734,833 (foam sclerotherapy gas-phase CO2 with controlled N2) and the likely US patent landscape
US Patent 8,734,833 is directed to a low-density foam for sclerotherapy (liquid phase containing a sclerosing agent; gas phase dominated by carbon dioxide with tightly limited nitrogen content; oxygen as the balance). The independent claim scope is driven by (i) the gas composition “consists essentially of” nitrogen/CO2/oxygen and (ii) functional physicochemical performance targets (foam density and half-life). Dependent claim carve-outs focus on narrower N2 ranges, narrower density/half-life windows, and preferred sclerosing agents (notably polidocanol with a specified vol/vol concentration in the liquid phase).
Because the claim set you provided is internally duplicated across claims 1/15/29 families, the effective claim estate is concentrated in a small number of claim pillars: gas composition, nitrogen window, and foam physicomechanics. That structure typically defines infringement risk for both competing foam-gas formulations and “workaround” products that change either the nitrogen percentage, shift the CO2 floor, or alter measured half-life/density while retaining polidocanol and the foam format.
What does US 8,734,833 actually claim: foam composition and “consists essentially of” gas-phase limits?
Core independent-claim elements (common across claims 1, 15, 29):
- A foam with:
- Liquid phase that comprises at least one sclerosing agent.
- Gas phase with defined constituents and a “consists essentially of” structure.
- Specific gas-phase composition:
- Nitrogen: 0.01% to 0.8% vol/vol (claims 1/15) or the same nitrogen window in variants (claims 29 and dependents).
- Carbon dioxide:
- “10% to 99.99% vol/vol” CO2 in claims 1/15.
- “at least 50% vol/vol” CO2 in claim 29 (stronger CO2 floor).
- Oxygen: the remaining gas, if any, consists essentially of oxygen (meaning oxygen is permitted; other gases are not, except to the extent they are compatible with the “consists essentially of” qualifier).
- Physicochemical performance targets (appearing as dependent limitations but important to practical scope):
- Foam density < 0.25 g/mL with half-life > 100 sec (claim 4 / 18 / 32).
- Half-life minimums: ≥120 sec (claim 5/19/33), ≥150 sec (claim 6/20/34), ≥180 sec (claim 7/21/35).
- Density ranges: multiple windows (claims 8-11 and 22-25 and 36-39) including 0.07–0.22 g/mL, 0.07–0.19, 0.07–0.16, and 0.08–0.14.
How broad are the gas composition bounds?
- Nitrogen tolerance is narrow relative to typical “gas blank” foam formulations. The maximum is 0.8 vol%, and the dependent claims narrow to 0.7 and 0.6.
- CO2 is the dominant gas.
- Claims 1/15 allow CO2 from 10% up to 99.99%.
- Claim 29 pushes the floor to ≥50% CO2, creating a more specific sub-genus.
- Oxygen is the only other permitted “remaining” gas.
- The phrase “remaining gas, if any, consisting essentially of oxygen” materially limits substitution with inert diluents beyond oxygen. A competing formulation introducing additional gases (even small amounts) can fall outside.
What does “consists essentially of” mean for infringement and workarounds?
Practically, “consists essentially of” blocks competitors from adding other gases that would materially affect the basic and novel characteristics of the invention. With oxygen as the only expressly allowed remainder, the key workaround lever is not simply “use CO2 foam,” but match the permitted gas inventory and avoid additional gases that could be considered outside the invention’s permitted composition.
Which elements are legally “hard” vs “soft”: gas makeup vs foam density/half-life
Hard composition limits (high infringement leverage):
- Nitrogen vol% is expressly bounded (0.01%–0.8%).
- CO2 vol% is expressly bounded or floored (10%–99.99% or ≥50%).
- “Remaining gas… consisting essentially of oxygen” limits other gas species.
Soft/functional limits (often decisive for product-specific proof):
- Foam density and half-life are not the independent-claim hooks in your list, but they become mandatory in multiple dependent claims (and therefore define how far a claim-by-claim infringement theory can be stretched).
- The performance minimums (≥100 sec, ≥120 sec, ≥150 sec, ≥180 sec) create measurable target infringement thresholds.
Business impact:
- A product matching gas composition may still avoid narrower dependent claims if its density/half-life measurements do not hit the defined windows under the patent’s measurement conditions.
- Conversely, a product missing the N2/CO2/oxygen composition can be outside the entire claim family regardless of performance metrics.
How are the dependent claims narrowing the independent claim?
Narrowing the nitrogen window (claims 2-3, 16-17, 30-31)
- Nitrogen 0.01%–0.7% (claim 2 / 16 / 30)
- Nitrogen 0.01%–0.6% (claim 3 / 17 / 31)
Effect: A competitor using nitrogen at 0.65–0.8 vol% is likely still within the independent claim but outside the narrower dependent tiers. That matters if the enforcement strategy targets dependent claims or if a jury will be instructed on specific dependent limitations.
Narrowing density and half-life (claims 4-11 and equivalents)
Dependent claims stack performance with composition:
- Density < 0.25 g/mL and half-life > 100 sec (claim 4 / 18 / 32)
- Half-life minima:
- ≥120 sec (claim 5 / 19 / 33)
- ≥150 sec (claim 6 / 20 / 34)
- ≥180 sec (claim 7 / 21 / 35)
- Density windows:
- 0.07–0.22 g/mL (claim 8 / 22 / 36)
- 0.07–0.19 g/mL (claim 9 / 23 / 37)
- 0.07–0.16 g/mL (claim 10 / 24 / 38)
- 0.08–0.14 g/mL (claim 11 / 25 / 39)
Effect: These are claim segmentation tools. If a competing foam is close on gas composition but misses half-life by a few seconds or density by a few hundredths of a gram per milliliter, the risk profile changes quickly from “direct hit” to “partial coverage.”
Preferred sclerosing agent selection (claims 12, 26, 40 and polidocanol subfamily claims 13-14, 27-28, 41-42)
- Sclerosing agent choices:
- Polidocanol, glycerol, sodium tetradecyl sulphate (claims 12/26/40)
- Polidocanol selected (claims 13/27/41)
- Polidocanol concentration (vol/vol in liquid phase):
- 0.5%–4% vol/vol (claims 14/28/42)
Effect: This is the main commercialization tether for EVA foam sclerotherapy products that use polidocanol. If a competitor uses a non-enumerated sclerosant, it may avoid these dependent claims while still potentially infringing the independent claims (if the independent claim only requires “at least one sclerosing agent”).
What is the practical “coverage map” across formulation variants?
Variant A: CO2-dominant foam with controlled nitrogen and oxygen remainder (highest risk)
Matches:
- N2: 0.01%–0.8 vol%
- CO2: at least 10% (or ≥50% for a sub-genus)
- Remaining gas: essentially oxygen
And typically uses polidocanol at 0.5%–4% vol/vol.
Exposure:
- Full independent-claim exposure if composition matches.
- Dependent-claim exposure increases if density and half-life meet the stacked thresholds.
Variant B: CO2 foam with similar nitrogen but different density/half-life (medium risk)
Exposure:
- May still infringe independent claims if composition matches.
- May avoid or reduce risk for narrower dependent claims.
Variant C: Adjust nitrogen above 0.8 vol% (structural workaround)
Exposure:
- Likely avoids independent claim if N2 exceeds the cap.
- Could still fall into non-identified other patents in the broader landscape, but not the 8,734,833 claim as given.
Variant D: Reduce CO2 below 10% or below 50% (structural workaround against sub-genus)
Exposure:
- If CO2 is below the relevant floor for the asserted claim version, that claim version falls.
- Other versions of the independent claim in the set still have lower CO2 floor (10%–99.99% in claim 1/15), so practical avoidance would require dropping CO2 below 10% or aligning with a different independent-claim version.
Variant E: Introduce other gases besides oxygen (compositional workaround)
Exposure:
- “Remaining gas… consisting essentially of oxygen” creates a barrier to inert substitution (eg, helium/argon) as remainder gas.
- Competitors must align with “consists essentially of” boundaries and the materiality of added gases.
Which therapeutic use does the patent target and how does that affect claim landscape?
The claim language is composition-based (foam with sclerosing agent) and does not explicitly recite anatomical indications. In the sclerotherapy context, that typically captures:
- Treatment of varicose veins and related vascular indications using sclerosants delivered via foam.
Business implication: Enforcement is usually against manufacturers/distributors of foam sclerosants where the delivered product has the claimed composition and physical profile, not against device-only components.
How likely is the rest of the US patent estate structured around this invention?
While you asked for a “patent landscape,” only the claim set for US 8,734,833 is provided here. Without the publication family, assignees, and citation trail, a reliable landscape cannot be fully enumerated. What can be stated from the claim architecture is how similar patents are commonly arranged around the same core concept:
Common adjacent US patent clusters you should expect around 8,734,833’s concept (based on claim pillars)
- Gas composition variants:
- Different nitrogen windows
- Different CO2 ranges (10%–99.99% vs ≥50% floors)
- Oxygen remainder constraints
- Foam performance variants:
- Additional density windows
- Additional half-life time ranges
- Sclerosant variants:
- Different sclerosant species or concentration ranges
- Measurement/validation methods:
- Protocols for density and half-life measurement
- Apparatus-defined half-life endpoint definitions
These clusters can be used to infer how an improved “next generation” foam formulation would be designed to escape the specific combination of N2/CO2/O2 and the performance thresholds.
Litigation and regulatory status: what can be concluded from the claim text alone?
No FDA regulatory status, Orange Book listing, or litigation record can be derived from the claim text you provided. A valid US exclusivity analysis requires linkage to:
- the specific marketed foam drug product (active + dosage form),
- the FDA application and approval date,
- Orange Book/NDA/BLA coding,
- and any PIV/PAR updates.
Given only the claims of US 8,734,833, litigation timing, Paragraph IV risk, and exclusivity expiration cannot be accurately mapped.
Key infringement tests for US 8,734,833 (what matters in a validity or infringement case)
1) Gas-phase composition assay
A product must be shown to have:
- N2 in the claimed range
- CO2 in the claimed range/floor (depending on which independent-claim variant is asserted)
- Remaining gas essentially oxygen
For enforcement, the most sensitive variable is typically the volumetric gas-phase composition at the time relevant to the product’s foam use and storage.
2) Presence and concentration of sclerosing agent
- For dependent claims that specify polidocanol, the polidocanol concentration (0.5%–4% vol/vol in liquid phase) becomes a threshold question.
- For the broader independent claims, the presence of any enumerated or non-enumerated sclerosing agent may still satisfy “at least one sclerosing agent,” depending on claim construction of “at least one” within the exact claim text (your list does not enumerate additional agent restrictions on the independent claim aside from claim 12/26/40 and polidocanol dependents).
3) Foam density and half-life
The performance-dependent claims require:
- density within a specified numeric range or below a maximum, and
- half-life above numeric thresholds.
In a product dispute, this is usually where test protocol definitions and repeatability become decisive.
Timeline and expiration: why it cannot be stated from the claim excerpt
Patent expiration depends on:
- application filing date,
- earliest priority date,
- whether any PTA/adjustments apply,
- and whether there are terminal disclaimers.
Those facts are not provided in the prompt. Without them, a precise “when does it lose exclusivity” timeline would be noncompliant with accuracy requirements.
Key takeaways
- US 8,734,833 claims a CO2-dominant foam for sclerotherapy where the gas phase has tight nitrogen and oxygen boundaries and where performance-based dependent claims require specific density and half-life targets.
- The strongest claim hooks are compositional: N2 is limited to 0.01%–0.8%, CO2 is 10%–99.99% (or ≥50% in one independent variant), and the remainder gas is essentially oxygen.
- Dependent claims add measurable constraints: half-life minimums (≥120/150/180 sec) and density bands (0.07–0.22 g/mL down to 0.08–0.14 g/mL).
- A major commercialization-relevant tether is the polidocanol sub-genus: 0.5%–4% vol/vol polidocanol in the liquid phase.
FAQs
1) What composition change most reliably avoids infringement of US 8,734,833?
Raising nitrogen above 0.8 vol% or changing the “remaining gas” so it is not essentially oxygen are the most direct compositional workarounds.
2) Does using polidocanol automatically fall under the polidocanol dependent claims?
No. The polidocanol-dependent claims require polidocanol at 0.5%–4% vol/vol in the liquid phase.
3) If a foam meets the gas composition but has a shorter half-life, what happens?
Gas composition may still satisfy the independent claims, but it may avoid or weaken coverage under the dependent claims that require specific half-life and density thresholds.
4) Are the 10% CO2 floor and the 50% CO2 floor both required?
They apply to different independent-claim variants in your set. Enforcement depends on which independent claim is asserted.
5) Can a competitor use other gases in small amounts for stability?
The claim language limits the remainder gas to “essentially oxygen,” so added inert gases beyond oxygen can risk falling outside the “consists essentially of” constraint.
